Hutchison China Meditech Limited Total Voting Rights (7012L)

TIDMHCM

RNS Number : 7012L

Hutchison China Meditech Limited

31 December 2018

Total Voting Rights

London: Monday, December 31, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2018, the issued share capital of Chi-Med consisted of 66,657,745 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 66,657,745 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

For illustrative purposes only, the 66,657,745 ordinary shares would be equivalent to 66,657,745 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 133,315,490 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President, 
   Corporate Finance & Development                               [phone] 
  David Dible, Citigate Dewe Rogerson                            [phone] (Mobile) 
                                                                 [e-mail] 
  Xuan Yang, Solebury Trout                                      [phone] (Mobile) 
                                                                  [e-mail] 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson         [phone] (Mobile) 
                                                                  [e-mail] 
  Americas - Brad Miles, Solebury Trout                          [phone] (Mobile) 
                                                                  [e-mail] 
  Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick           [phone] (Mobile) 
                                                                  [e-mail] 
                                                     Zhou Yi,    [phone] (Mobile) 
                                                     Brunswick    [e-mail] 
  Mainland China - Sam Shen, Edelman                             [phone] (Mobile) 
                                                                  [e-mail] 
 
Nominated Advisor 
  Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited       [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TVREANAPADPPFEF

(END) Dow Jones Newswires

December 31, 2018 02:00 ET (07:00 GMT)